Table 3.
Physicochemical properties of currently used drugs for kinetoplastid infections
| Compound | MW | clogPa | HBDb | HBAb | PSA | RO5 |
|---|---|---|---|---|---|---|
| Suramin | 1297 | 2·2 | 12 | 23 | 468 | N |
| Pentamidine | 340 | 2·8 | 6 | 4 | 118 | N |
| Melarsoprol | 398 | 1·7 | 6 | 4 | 123 | N |
| Eflornithine | 182 | −3·7 | 5 | 4 | 89 | Y |
| Nifurtimox | 273 | −0·2 | 0 | 7 | 109 | Y |
| Benznidazole | 260 | 0·7 | 1 | 4 | 93 | Y |
| Amphotericin B | 924 | −1·2 | 13 | 18 | 320 | N |
| Miltefosine | 408 | 6·0 | 0 | 4 | 56 | N |
| Paramomycin | 616 | −3·0 | 18 | 20 | 347 | N |
| Stibogluconatec | 680 | −3·5 | 8 | 17 | 276 | N |
| Meglumine antimoniatec | 366 | 7 | 9 | N |
a
clogP was calculated using StarDrop™.
b
HDB and HBA are given as defined by Lipinski (Lipinski et al. 2001).
c
The precise structures of stibogluconate and meglumine antimoniate are not known.